Physician profile
Dwayne Christopher Steele
NPI 1518294016
$7,131.45
in general payments reported to CMS, 2019-2025
38 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,112 · 2022: $1,127 · 2023: $1,158 · 2024: $1,541 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,892.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,346.43 | 2021 | |
| Novo Nordisk INC | $1,004.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $741.44 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $589.16 | 2021-2025 | |
| Lilly USA, LLC | $557.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $403.59 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $326.48 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals Lp | $291.24 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $247.93 | 2022-2025 | |
| Gilead Sciences, INC. | $200.50 | 2024-2025 | |
| Exact Sciences Corporation | $188.74 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $168.81 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $151.89 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $131.69 | 2023-2025 | Otezla, Repatha, Repatha |
| Biohaven Pharmaceutical Holding Company Ltd. | $124.75 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwayne Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.